Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Had some time on my hands a couple of days ago coupled with knowing that the # of patients where poziotinib may be an effective therapy is doubled, and then seeing an analyst's name pop up who used to follow SPPI but stopped after the Fusilev disaster, I decided to send the analyst an email on the merits of SPPI. You never know, it can't hurt. Figured I'd post it hear too.

Dear XXX, while not a subscriber, I am aware of the biotechs you analyze via email notifications from your blog and am invested in one you recommend, XXX, but I first became aware of your analysis when you followed Spectrum Pharma until they had that disaster of an earnings report due to the Fusilev shortfall. I stayed w them even though I didn’t trust Dr. Raj. Well, they got rid of Dr. Raj as CEO near the end of last year and he is not on this year’s Proxy for election to the BOD scheduled for June. In fact, at the earnings CC, it was mentioned they are in litigation with him. Recently, they improved their corporate governance (http://investor.sppirx.com/index.php/news-releases/news-release-details/spectrum-pharmaceuticals-announces-corporate-governance) w separation of CEO and BOD chair and getting rid of the poison pill as some of the improvements. You know about some of their ‘boring’ cancer drugs that bring in about $110M a year to help pay for development, and they have a biobetter to Neulasta ($4B market) in development with BLA submittal in the 4th Q but their gem, and really the reason I’m touching base with you, is poziotinib, a TKI targeted therapy for EGFR and HER2 exon 20 insertion mutations in NSCLC where there are no drugs that are effective. Spectrum really lucked out in that MD Anderson made that discovery and they have just signed off on a licensing agreement (http://investor.sppirx.com/news-releases/news-release-details/spectrum-pharmaceuticals-announces-exclusive-licensing-agreement ). There are ~19,700 patients in the US, EU, and Japan who get this particular cancer (Spectrum presentation) and over double that amount if you include those that have this mutation in some 20 other cancer indications per MD Anderson (video

) with a basket trial in development. MDA reported very interim phase 2 study data at Word Lung back in Sept (PR http://investor.sppirx.com/releasedetail.cfm?ReleaseID=1044288 with must see video linked within PR) and 4 months more mature data PR’d last month (http://investor.sppirx.com/news-releases/news-release-details/spectrum-pharmaceuticals-announces-publication-poziotinib-data ) noting that the data was published in Nature Medicine. The interim data shows that at 6.6 months mPFS hasn’t been reached yet for the 1st 11 EGFR pts where with current Standard of Care PFS is 1.9m. A more comprehensive data readout will be reported by MDA at WCLC in Sept. An asymmetrical investment if I ever saw one. I can go on and on but here are some posts I wrote recently so as not to reinvent the wheel and if [you are] interested [can read].
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140525750
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140621347
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140639254
Would be interesting to know of your interest.
Regards,
antihama